查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1738341

牛皮癬藥物市場－全球產業規模、佔有率、趨勢、機會及預測，依治療類型、作用機制、給藥途徑、地區及競爭情況細分，2020-2030 年預測

Psoriasis Drugs Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Type of Treatment, By Mechanism of Action, By Route of Administration, By Region & Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 183 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球乾癬藥物市場規模達 210.6 億美元，預計到 2030 年將以 6.57% 的複合年成長率成長，在預測期末達到可觀的市場規模。受全球銀屑病發病率上升、治療手段不斷進步以及對更有效和個性化治療的需求不斷成長的推動，該市場正在快速發展。乾癬是一種慢性自體免疫疾病，會導致皮膚發紅、發炎和鱗狀病變，影響全球數百萬人，並嚴重影響生活品質。隨著認知度和診斷能力的提高，乾癬的識別和治療正變得越來越普遍。銀屑病的治療方法多種多樣，涵蓋外用藥物、光療、全身用藥和生物療法。尤其是生物製劑，它透過提供更高的療效和安全性，徹底改變了治療模式。隨著研究的不斷深入、醫療政策的支持以及患者對標靶治療需求的不斷成長，銀屑病藥物市場在全球範圍內持續成長。

市場概覽
預測期 2026-2030
2024年市場規模 210.6億美元
2030年市場規模 306億美元
2025-2030 年複合年成長率 6.57%
成長最快的領域 口服
最大的市場 北美洲

關鍵市場促進因素

牛皮癬盛行率不斷上升

主要市場挑戰

對牛皮癬病因和誘因的了解有限

主要市場趨勢

生物療法占主導地位

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：全球牛皮癬藥物市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依治療類型（生物藥物、小分子系統藥物、熱帶療法）
    • 依作用機制分類（TNF α 抑制劑、PDE4 抑制劑、白血球介素抑制劑等）
    • 依給藥途徑（口服、腸胃外、外用）
    • 按地區
    • 按公司分類（2024）
  • 市場地圖

第6章：北美銀屑病藥物市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲牛皮癬藥物市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙

第8章：亞太地區乾癬藥物市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：南美牛皮癬藥物市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第10章：中東與非洲牛皮癬藥物市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 最新動態
  • 產品發布
  • 併購

第 13 章：全球牛皮癬藥物市場：SWOT 分析

第 14 章：競爭格局

  • Glanbia Plc
  • Pfizer Inc.
  • Bayer AG
  • Amway Corp.
  • GlaxoSmithKline plc.
  • Good Health New Zealand
  • The Nature's Bounty Co.
  • NOW Foods
  • Abbott
  • Herbalife Nutrition

第 15 章：策略建議

第16章調查會社について,免責事項

簡介目錄
Product Code: 16213

Global Psoriasis Drugs Market has been valued at USD 21.06 billion in 2024 and is expected to grow at a CAGR of 6.57% through 2030, reaching significant market size by the end of the forecast period. This market is evolving rapidly, driven by the increasing global incidence of psoriasis, ongoing therapeutic advancements, and rising demand for more effective and personalized treatments. Psoriasis is a chronic autoimmune disorder that results in red, inflamed, and scaly skin lesions, affecting millions of people worldwide and significantly impacting quality of life. As awareness and diagnostic capabilities improve, the identification and treatment of psoriasis are becoming more prevalent. The therapeutic landscape is diverse, spanning topical agents, phototherapy, systemic drugs, and biologic therapies. Biologics, in particular, have transformed the treatment paradigm by offering enhanced efficacy and safety. With expanding research, supportive healthcare policies, and increasing patient demand for targeted treatments, the psoriasis drugs market continues to gain momentum across global regions.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 21.06 Billion
Market Size 2030USD 30.60 Billion
CAGR 2025-20306.57%
Fastest Growing SegmentOral
Largest MarketNorth America

Key Market Drivers

Increasing Prevalence of Psoriasis

The rising prevalence of psoriasis globally is a key driver for the market. This autoimmune condition, characterized by an overproduction of skin cells, results in painful, itchy, and inflamed patches. The likelihood of developing psoriasis increases with genetic predisposition, which is being amplified as populations grow and awareness of the disease improves. According to a 2025 NIH report, Spain saw a 43.3% increase in psoriasis cases from 2022, growing from 692,317 to 991,832. This significant rise illustrates the expanding patient base. Moreover, modern environmental and lifestyle factors-such as heightened stress, smoking, poor diet, and exposure to pollution-are contributing to the disease's growing incidence. Enhanced diagnostic practices also play a role, allowing more cases, including milder forms, to be correctly identified and treated. Collectively, these factors are intensifying the demand for innovative and effective treatment options.

Key Market Challenges

Limited Understanding of Psoriasis Causes and Triggers

One of the most significant challenges in managing psoriasis is the limited understanding of its exact causes and triggers. As a multifactorial autoimmune disorder, psoriasis involves complex interactions between genetic, environmental, and immune system factors. The variability in genetic markers among patients complicates the development of universal or targeted therapies. Additionally, triggers such as stress, infections, and certain medications vary widely from person to person, making individualized treatment approaches challenging. This lack of clarity in disease etiology hinders the development of more precise treatments and limits the potential for personalized medicine in psoriasis care. It also poses difficulties for clinicians in predicting flare-ups and selecting optimal therapeutic strategies.

Key Market Trends

Biologic Therapies Dominating Treatment Approaches

A leading trend in the Global Psoriasis Drugs Market is the rising dominance of biologic therapies. These advanced drugs, derived from living organisms, specifically target key immune system pathways responsible for psoriasis, such as cytokines and immune cell receptors. Biologics have shown superior results compared to conventional treatments, offering greater symptom relief and fewer side effects. This has led to a shift in clinical preference, especially for moderate to severe psoriasis cases. Their ability to provide sustained remission has positioned biologics as a mainstay in psoriasis management. The trend is further supported by ongoing drug development and approvals, making these therapies increasingly accessible and expanding the market for targeted biologic solutions.

Key Market Players

  • Glanbia Plc
  • Pfizer Inc.
  • Bayer AG
  • Amway Corp.
  • GlaxoSmithKline plc.
  • Good Health New Zealand
  • The Nature's Bounty Co.
  • NOW Foods
  • Abbott
  • Herbalife Nutrition

Report Scope:

In this report, the Global Psoriasis Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Psoriasis Drugs Market, By Type of Treatment:

  • Biologic Drugs
  • Small Molecule Systemic Drugs
  • Tropical Therapies

Psoriasis Drugs Market, By Mechanism of Action:

  • TNF Alpha Inhibitors
  • PDE4 Inhibitors
  • Interleukin Inhibitors
  • Others

Psoriasis Drugs Market, By Route of Administration:

  • Oral
  • Parenteral
  • Topical

Psoriasis Drugs Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Psoriasis Drugs Market.

Available Customizations:

Global Psoriasis Drugs market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Route of Administrations
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Psoriasis Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type of Treatment (Biologic Drugs, Small Molecule Systemic Drugs, Tropical Therapies)
    • 5.2.2. By Mechanism of Action (TNF Alpha Inhibitors, PDE4 Inhibitors, Interleukin Inhibitors, Others)
    • 5.2.3. By Route of Administration (Oral, Parenteral, Topical)
    • 5.2.4. By Region
    • 5.2.5. By Company (2024)
  • 5.3. Market Map

6. North America Psoriasis Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type of Treatment
    • 6.2.2. By Mechanism of Action
    • 6.2.3. By Route of Administration
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Psoriasis Drugs Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type of Treatment
        • 6.3.1.2.2. By Mechanism of Action
        • 6.3.1.2.3. By Route of Administration
    • 6.3.2. Canada Psoriasis Drugs Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type of Treatment
        • 6.3.2.2.2. By Mechanism of Action
        • 6.3.2.2.3. By Route of Administration
    • 6.3.3. Mexico Psoriasis Drugs Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type of Treatment
        • 6.3.3.2.2. By Mechanism of Action
        • 6.3.3.2.3. By Route of Administration

7. Europe Psoriasis Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type of Treatment
    • 7.2.2. By Mechanism of Action
    • 7.2.3. By Route of Administration
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Psoriasis Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type of Treatment
        • 7.3.1.2.2. By Mechanism of Action
        • 7.3.1.2.3. By Route of Administration
    • 7.3.2. United Kingdom Psoriasis Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type of Treatment
        • 7.3.2.2.2. By Mechanism of Action
        • 7.3.2.2.3. By Route of Administration
    • 7.3.3. Italy Psoriasis Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecasty
        • 7.3.3.2.1. By Type of Treatment
        • 7.3.3.2.2. By Mechanism of Action
        • 7.3.3.2.3. By Route of Administration
    • 7.3.4. France Psoriasis Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type of Treatment
        • 7.3.4.2.2. By Mechanism of Action
        • 7.3.4.2.3. By Route of Administration
    • 7.3.5. Spain Psoriasis Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type of Treatment
        • 7.3.5.2.2. By Mechanism of Action
        • 7.3.5.2.3. By Route of Administration

8. Asia-Pacific Psoriasis Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type of Treatment
    • 8.2.2. By Mechanism of Action
    • 8.2.3. By Route of Administration
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Psoriasis Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type of Treatment
        • 8.3.1.2.2. By Mechanism of Action
        • 8.3.1.2.3. By Route of Administration
    • 8.3.2. India Psoriasis Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type of Treatment
        • 8.3.2.2.2. By Mechanism of Action
        • 8.3.2.2.3. By Route of Administration
    • 8.3.3. Japan Psoriasis Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type of Treatment
        • 8.3.3.2.2. By Mechanism of Action
        • 8.3.3.2.3. By Route of Administration
    • 8.3.4. South Korea Psoriasis Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type of Treatment
        • 8.3.4.2.2. By Mechanism of Action
        • 8.3.4.2.3. By Route of Administration
    • 8.3.5. Australia Psoriasis Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type of Treatment
        • 8.3.5.2.2. By Mechanism of Action
        • 8.3.5.2.3. By Route of Administration

9. South America Psoriasis Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type of Treatment
    • 9.2.2. By Mechanism of Action
    • 9.2.3. By Route of Administration
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Psoriasis Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type of Treatment
        • 9.3.1.2.2. By Mechanism of Action
        • 9.3.1.2.3. By Route of Administration
    • 9.3.2. Argentina Psoriasis Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type of Treatment
        • 9.3.2.2.2. By Mechanism of Action
        • 9.3.2.2.3. By Route of Administration
    • 9.3.3. Colombia Psoriasis Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type of Treatment
        • 9.3.3.2.2. By Mechanism of Action
        • 9.3.3.2.3. By Route of Administration

10. Middle East and Africa Psoriasis Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type of Treatment
    • 10.2.2. By Mechanism of Action
    • 10.2.3. By Route of Administration
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Psoriasis Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type of Treatment
        • 10.3.1.2.2. By Mechanism of Action
        • 10.3.1.2.3. By Route of Administration
    • 10.3.2. Saudi Arabia Psoriasis Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type of Treatment
        • 10.3.2.2.2. By Mechanism of Action
        • 10.3.2.2.3. By Route of Administration
    • 10.3.3. UAE Psoriasis Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type of Treatment
        • 10.3.3.2.2. By Mechanism of Action
        • 10.3.3.2.3. By Route of Administration

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Psoriasis Drugs Market: SWOT Analysis

14. Competitive Landscape

  • 14.1. Glanbia Plc
    • 14.1.1. Business Overview
    • 14.1.2. Mechanism of Action Offerings
    • 14.1.3. Recent Developments
    • 14.1.4. Key Personnel
    • 14.1.5. SWOT Analysis
  • 14.2. Pfizer Inc.
  • 14.3. Bayer AG
  • 14.4. Amway Corp.
  • 14.5. GlaxoSmithKline plc.
  • 14.6. Good Health New Zealand
  • 14.7. The Nature's Bounty Co.
  • 14.8. NOW Foods
  • 14.9. Abbott
  • 14.10. Herbalife Nutrition

15. Strategic Recommendations

16. About Us & Disclaimer